The AASLD also recommends HBsAg positive individuals with an annual HCC risk greater than 0.2% per year to receive hepatocellular carcinoma (HCC) surveillance with biannual liver ultrasound with or without blood levels of alfa-fetoprotein (AFP). The gene discussed is AFP; the disease is hepatocellular carcinoma.